Exelixis Inc Depreciation
Exelixis Inc (EXEL) reported Depreciation of $25.70 million for the 12-month period ending 2023-12-29, per its 10-K filed 2024-02-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2024-02-06
- Exelixis Inc depreciation for the quarter ending 2020-01-03 was $2.20M, a 10.00% increase year-over-year.
- Exelixis Inc depreciation for the quarter ending 2019-09-27 was $2.10M, a 23.53% increase year-over-year.
- Exelixis Inc depreciation for the quarter ending 2019-06-28 was $2.00M, a 150.00% increase year-over-year.
- Exelixis Inc depreciation for the quarter ending 2019-03-29 was $2.00M, a 400.00% increase year-over-year.
- Exelixis Inc depreciation for fiscal 2023 was $25.70M, a 22.97% increase from fiscal 2022.
- Exelixis Inc depreciation for fiscal 2022 was $20.90M, a 53.68% increase from fiscal 2021.
- Exelixis Inc depreciation for fiscal 2021 was $13.60M, a 49.45% increase from fiscal 2021.
- Exelixis Inc depreciation for fiscal 2021 was $9.10M, a 9.64% increase from fiscal 2020.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 6 month as first filed | Depreciation 9 month | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-12-29 | $25.70M 10-K · filed 2024-02-06 | |||||
| 2022-12-30 | $20.90M 10-K · filed 2024-02-06 | |||||
| 2021-12-31 | $13.60M 10-K · filed 2024-02-06 | |||||
| 2021-01-01 | $9.10M 10-K · filed 2023-02-07 | |||||
| 2020-01-03 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $4.30M derived: sum of 2 quarters · filed 2022-02-18 | $6.30M derived: sum of 3 quarters · filed 2022-02-18 | $8.30M 10-K · filed 2022-02-18 | ||
| 2019-09-27 | $2.10M 10-Q · filed 2019-10-30 | $4.10M derived: sum of 2 quarters · filed 2019-10-30 | $6.10M 10-Q · filed 2019-10-30 | $8.10M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2019-06-28 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $4.00M 10-Q · filed 2019-07-31 | $6.00M derived: sum of 3 quarters · filed 2020-02-25 | $7.70M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2019-03-29 | $2.00M 10-Q · filed 2019-05-01 | $4.00M derived: sum of 2 quarters · filed 2020-02-25 | $5.70M derived: sum of 3 quarters · filed 2020-02-25 | $6.50M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-12-28 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $3.70M derived: sum of 2 quarters · filed 2020-02-25 | $4.50M derived: sum of 3 quarters · filed 2020-02-25 | $4.90M 10-K · filed 2021-02-11 | ||
| 2018-09-28 | $1.70M 10-Q · filed 2019-10-30 | $2.50M derived: sum of 2 quarters · filed 2019-10-30 | $2.90M 10-Q · filed 2019-10-30 | $3.30M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-06-29 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $1.20M 10-Q · filed 2019-07-31 | $1.60M derived: sum of 3 quarters · filed 2020-02-25 | $1.80M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-03-30 | $400.00K 10-Q · filed 2019-05-01 | $800.00K derived: sum of 2 quarters · filed 2020-02-25 | $1.00M derived: sum of 3 quarters · filed 2020-02-25 | |||
| 2017-12-29 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $600.00K derived: sum of 2 quarters · filed 2020-02-25 | $1.20M 10-K · filed 2020-02-25 | |||
| 2017-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $800.00K 10-Q · filed 2017-11-01 | ||||
| 2017-09-29 | $300.00K 10-Q · filed 2018-11-01 | $800.00K 10-Q · filed 2018-11-01 | ||||
| 2017-06-30 | $600.00K 10-Q · filed 2018-08-01 | $500.00K 10-Q · filed 2017-08-02 | ||||
| 2017-03-31 | $300.00K 10-Q · filed 2018-05-02 | $500.00K derived: sum of 2 quarters · filed 2018-05-02 | $800.00K derived: sum of 3 quarters · filed 2018-05-02 | |||
| 2016-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $500.00K derived: sum of 2 quarters · filed 2017-11-01 | $1.00M 10-K · filed 2017-02-27 | |||
| 2016-12-30 | $1.00M 10-K · filed 2019-02-22 | |||||
| 2016-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $800.00K 10-Q · filed 2017-11-01 | ||||
| 2016-06-30 | $500.00K 10-Q · filed 2017-08-02 | |||||
| 2016-01-01 | $1.40M 10-K · filed 2018-02-26 | |||||
| 2015-12-31 | $1.40M 10-K · filed 2017-02-27 | |||||
| 2014-12-31 | $2.40M 10-K · filed 2017-02-27 | $2.30M 10-K · filed 2015-03-02 | ||||
| 2013-12-31 | $3.10M 10-K · filed 2016-02-29 | |||||
| 2012-12-31 | $4.80M 10-K · filed 2015-03-02 | $4.81M 10-K · filed 2013-02-21 | ||||
| 2011-12-31 | $6.80M 10-K · filed 2014-02-20 | $6.82M 10-K · filed 2013-02-21 | ||||
| 2010-12-31 | $10.50M 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |